Found 11 results
Author Title [ Type(Desc)] Year
Filters: Author is Goll, Johannes B  [Clear All Filters]
Journal Article
L. M. Howard, Goll, J. B., Jensen, T. L., Hoek, K. L., Prasad, N., Gelber, C. E., Levy, S. E., Joyce, S., Link, A. J., C Creech, B., and Edwards, K. M., “AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells.”, J Infect Dis, vol. 219, no. 11, pp. 1786-1798, 2019.
I. N. Mbawuike, Atmar, R. L., Patel, S. M., Corry, D. B., Winokur, P. L., Brady, R. C., Chen, W. H., Edwards, K. M., C Creech, B., Walter, E. B., Frey, S. E., Belshe, R. B., Goll, J. B., Hill, H., and Keitel, W. A., “Cell Mediated Immune Responses Following Revaccination with an Influenza A/H5N1 Vaccine”, Vaccine, vol. 34, no. 4, pp. 547-554, 2016.
S. E. Frey, Wald, A., Edupuganti, S., Jackson, L. A., Stapleton, J. T., Sahly, H. El, El-Kamary, S. S., Edwards, K., Keyserling, H., Winokur, P., Keitel, W., Hill, H., Goll, J. B., Anderson, E. L., Graham, I. L., Johnston, C., Mulligan, M., Rouphael, N., Atmar, R., Patel, S., Chen, W., Kotloff, K., C Creech, B., Chaplin, P., and Belshe, R. B., “Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.”, Vaccine, vol. 33, no. 39, pp. 5225-34, 2015.
S. Ross, Pati, P., Jensen, T. L., Goll, J. B., Gelber, C. E., Singh, A., McNeal, M., Boppana, S. B., and Bernstein, D. I., “Cytomegalovirus genetic diversity following primary infection.”, J Infect Dis, 2019.
F. Hamzabegovic, Goll, J. B., Hooper, W. F., Frey, S., Gelber, C. E., and Abate, G., “Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.”, NPJ Vaccines, vol. 5, p. 6, 2020.
M. A. Minaya, Jensen, T. L., Goll, J. B., Korom, M., Datla, S. H., Belshe, R. B., and Morrison, L. A., “Molecular Evolution of Herpes Simplex Virus 2 Complete Genomes: Comparison between Primary and Recurrent Infections”, J Virol, vol. 91, no. 23, pp. e00942-17, 2017.
E. J. Anderson, Lai, L., Wrammert, J., Kabbani, S., Xu, Y., Priyamvada, L., Hill, H., Goll, J. B., Jensen, T. L., Kao, C., Yildirim, I., Rouphael, N., Jackson, L., and Mulligan, M. J., “Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine.”, Vaccines (Basel), vol. 8, no. 1, 2020.
T. L. Jensen, Frasketi, M., Conway, K., Villarroel, L., Hill, H., Krampis, K., and Goll, J. B., “RSEQREP: RNA-Seq Reports, an open-source cloud-enabled framework for reproducible RNA-Seq data processing, analysis, and result reporting.”, F1000Res, vol. 6, p. 2162, 2018.
L. A. Jackson, Frey, S. E., Sahly, H. M. El, Mulligan, M. J., Winokur, P. L., Kotloff, K. L., Campbell, J. D., Atmar, R. L., Graham, I., Anderson, E. J., Anderson, E. L., Patel, S. M., Fields, C., Keitel, W., Rouphael, N., Hill, H., and Goll, J. B., “Safety and Immunogenicity of a Modified Vaccinia Ankara Vaccine Using Three Immunization Schedules and Two Modes of Delivery: A Randomized Clinical Non-Inferiority Trial”, Vaccine, vol. 35, no. 13, pp. 1675-1682, 2017.
M. S. Natrajan, Rouphael, N., Lai, L., Kazmin, D., Jensen, T. L., Weiss, D. S., Ibegbu, C., Sztein, M. B., Hooper, W. F., Hill, H., Anderson, E. J., Johnson, R., Sanz, P., Pulendran, B., Goll, J. B., and Mulligan, M. J., “Systems Vaccinology for a Live Attenuated Tularemia Vaccine Reveals Unique Transcriptional Signatures That Predict Humoral and Cellular Immune Responses.”, Vaccines (Basel), vol. 8, no. 1, 2019.
M. J. Mulligan, Stapleton, J. T., Keitel, W. A., Frey, S. E., Chen, W. H., Rouphael, N., Edupuganti, S., Beck, A., Winokur, P. L., Sahly, H. M. El, Patel, S. M., Atmar, R. L., Graham, I., Anderson, E., El-Kamary, S. S., Pasetti, M. F., Sztein, M. B., Hill, H., and Goll, J. B., “Tularemia Vaccine: Safety, Reactogenicity, "Take" Skin Reactions, and Antibody Responses Following Vaccination with a New Lot of the Francisella Tularensis Live Vaccine Strain - A Phase 2 Randomized Clinical Trial”, Vaccine, vol. 35, no. 36, pp. 4730-4737, 2017.